ElastoMRI Evaluation of Hepatic Metastases in Colorectal Cancer ( MetaIRM)

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Aug 12, 2024

Keywords

ClinConnect Summary

The MetaIRM clinical trial is studying how a special type of MRI, called elastography, can help doctors better understand how well patients with colorectal cancer and liver metastases are responding to chemotherapy. Right now, doctors look at tissue samples after surgery to see how well the treatment worked, but this method isn't always reliable. The goal of this trial is to use elastography to measure changes in the stiffness of the liver tissue caused by different treatments, including standard chemotherapy and targeted therapies, which may give a clearer picture of how effective the treatment is before surgery.

To participate in this trial, you need to be an adult (18 years or older) who has been diagnosed with colorectal cancer that has spread to the liver. You should have at least one liver metastasis larger than 2 cm and be scheduled to start your first line of chemotherapy. However, there are some exclusions, such as being pregnant or having certain medical conditions that prevent you from undergoing an MRI. If you join the study, you can expect to have an MRI that measures the stiffness of your liver tissue, which may help improve treatment plans in the future. This study is not yet recruiting participants, but it aims to provide important insights into better treatment monitoring for colorectal cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients ≥18 years old, followed for colorectal cancer with hepatic metastases.
• • The diagnosis of metastasis can be made: either by tumor biopsy or by the appearance during follow-up of colorectal cancer of at least one liver lesion with the characteristics of metastasis (fibrous tumor type imaging)
• • Patient with an indication to receive first-line chemotherapy for liver metastases, whether or not associated with targeted therapy
• • Patient with at least one hepatic metastasis greater than 2cm
• Exclusion Criteria:
• • Patients not affiliated with social security
• • Pregnant or breastfeeding women
• • Patients under guardianship, curatorship or safeguard of justice
• • Patients with a contraindication to MRI or to the injection of contrast agent in MRI. The classic contraindications for MRI are defined by the French Society of Radiology:http://www.sfrnet.org/sfr/professionnels/1-fiche-information-patients/irm/index.phtml
• • Lack of signed patient consent